Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.63 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.63 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.56 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.47 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.47 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.47 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.47 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.47 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.54 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.52 |
| ▸ | BRS3 | P32247 | 1/20 | 0.50 |
| ▸ | BDKRB1 | P46663 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535 | 0.98 | SLC6A3 (0.65) | SLC6A3SLC6A4SLC6A2LOXL2LTB4R2 | |
| SCHEMBL3112718 | 0.86 | SLC6A3 (0.69) | SLC6A3SLC6A4SLC6A2LTB4R2BRS3 | |
| SCHEMBL14326964 | 0.86 | SLC6A3 (0.69) | SLC6A3SLC6A4SLC6A2LTB4R2BRS3 | |
| SCHEMBL29979869 | 0.86 | SLC6A3 (0.69) | SLC6A3SLC6A4SLC6A2LTB4R2BRS3 | |
| SCHEMBL5475393 | 0.85 | LOXL2 (0.57) | SLC6A3SLC6A4SLC6A2LOXL2ALDH1A1 | |
| SCHEMBL2642187 | 0.84 | SLC6A3 (0.67) | SLC6A3SLC6A4SLC6A2LTB4R2BRS3 | |
| SCHEMBL8220001 | 0.84 | TSHR (0.57) | SLC6A3SLC6A4LTB4R2ALDH1A1HSD17B10 | |
| SCHEMBL27843639 | 0.84 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2ALDH1A1CFTR | |
| Bromide SCHEMBL8670915 | 0.83 | SLC6A3 (0.65) | SLC6A3SLC6A4SLC6A2LTB4R2BRS3 | |
| SCHEMBL8539999 | 0.83 | SLC6A3 (0.69) | SLC6A3SLC6A4SLC6A2LTB4R2BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673889-B2 | BLT2-mediated disease, BLT2 binding agent and the compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2172222-A2 | Novel BLT2-mediated disease, BLT2-binding agent and compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1745800-A1 | NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-24 | — | — | EP | disclosed |
| US-7091380-B2 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1476419-B1 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | MERCK & CO INC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050085667-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | MERCK SHARP & DOHME LLC | 2005-04-21 | — | — | US | disclosed |
| EP-0733366-B1 | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics | DU PONT (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0324377-B1 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | DU PONT (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0733366-A2 | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5138069-A | Treating hypertension and congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| US-5128355-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| US-5093346-A | Hypotensive agents, congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-03-03 | — | — | US | disclosed |
| US-5081127-A | Hypotensive agents and treatment of congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| US-5043349-A | Hypotensive agents, treatment of congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-08-27 | — | — | US | disclosed |
| US-5015651-A | Triazole derivatives for treatment of congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
| EP-0323841-A2 | Substituted pyrrole, pyrazole and triazole angiotensin II antagonists | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-12 | — | — | EP | disclosed |
| EP-0253310-A2 | Angiotensin II receptor blocking imidazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | MALT1, SLC10A2, LCP2 | SLC6A3 134/4885SLC6A4 305/4885SLC6A2 136/4885 |
| US-20050085667-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, LTB4R2 | SLC6A3 3890/4885SLC6A4 2252/4885SLC6A2 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.